Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 24 Jan, 2021
  • 2 locations
Efficacy of G-CSF-Priming in Elderly AML Patients

versus the same IdAV chemotherapy only followed by G-CSF (without priming) in elderly patients with de novo AML, secondary AML and advanced MDS. Moreover, the ability to mobilize sufficient

idarubicin
consolidation therapy
neoadjuvant therapy
cell transplantation
fludarabine
  • 50 views
  • 07 Nov, 2020
  • 1 location
Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients

unrelated donors in patients with MDS or secondary AML. The hypothesis is that dose-reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year after allogeneic stem

cell transplantation
busulfan
cyclophosphamide
fludarabine
  • 28 views
  • 07 Nov, 2020
  • 1 location
CD8 Depleted Non-engrafting HLA Mismatched Unrelated Infusion With MDS and Secondary AML

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.

anemia
hydroxyurea
acute leukemia
leukemia
decitabine
  • 0 views
  • 22 Aug, 2021
  • 1 location
Uproleselan Cladribine and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute

  • 0 views
  • 05 Jul, 2021
  • 1 location
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old

cancer
leukemia
cytarabine
ejection fraction
daunorubicin
  • 0 views
  • 11 Aug, 2021
  • 2 locations
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.

filgrastim
mitoxantrone
colony stimulating factor
cytarabine
ejection fraction
  • 28 views
  • 09 Apr, 2021
  • 1 location
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

This phase II trial studies how well lenalidomide works in treating patients with acute myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of cancer, although cancer still may be in the body and may be likely to come back or spread. Biological therapies, such …

stem cell transplantation
flow cytometry
lenalidomide
dysplasia
cancer
  • 42 views
  • 26 Jun, 2021
  • 2 locations
A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, or

secondary acute myeloid leukemia
refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia
  • 0 views
  • 30 Jul, 2021
  • 9 locations
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

This phase IB/II trial studies the best dose of TP-0903 and how well it works when given alone or with azacitidine in treating patients with FLT3 gene mutated acute myeloid leukemia. TP-0903 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy …

  • 0 views
  • 27 Jan, 2021
  • 1 location